Arcutis Biotherapeutics (ARQT) Set to Post Quarterly Earnings on Wednesday

Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to be releasing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Arcutis Biotherapeutics to announce earnings of $0.18 per share and revenue of $142.59 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Arcutis Biotherapeutics (NASDAQ:ARQT) last posted its earnings results on Wednesday, August 5th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.06 by $0.05. The firm had revenue of $129.86 million during the quarter, compared to analysts’ expectations of $118.85 million. Arcutis Biotherapeutics had a net margin of 6.15% and a return on equity of 15.05%. On average, analysts expect Arcutis Biotherapeutics to post $0.43 EPS for the current fiscal year and $1.06 EPS for the next fiscal year.

Arcutis Biotherapeutics Stock Performance

ARQT opened at $31.26 on Tuesday. The business’s 50 day moving average is $26.78 and its 200-day moving average is $25.30. The stock has a market cap of $3.93 billion, a PE ratio of 148.86 and a beta of 1.57. The company has a current ratio of 2.92, a quick ratio of 2.67 and a debt-to-equity ratio of 0.46. Arcutis Biotherapeutics has a twelve month low of $19.30 and a twelve month high of $33.30.

Insider Buying and Selling at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, insider Masaru Matsuda sold 3,674 shares of the business’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $25.00, for a total transaction of $91,850.00. Following the sale, the insider directly owned 112,508 shares of the company’s stock, valued at $2,812,700. The trade was a 3.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Howard G. Welgus sold 4,728 shares of the firm’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $26.93, for a total value of $127,325.04. Following the sale, the director owned 35,207 shares of the company’s stock, valued at $948,124.51. The trade was a 11.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 77,393 shares of company stock valued at $1,971,944. 9.40% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts recently issued reports on ARQT shares. Cantor Fitzgerald began coverage on Arcutis Biotherapeutics in a report on Thursday, October 15th. They issued an “overweight” rating and a $48.00 price objective for the company. Guggenheim lifted their target price on Arcutis Biotherapeutics from $38.00 to $44.00 and gave the company a “buy” rating in a research note on Monday, October 19th. Wall Street Zen lowered Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 10th. Morgan Stanley boosted their price target on Arcutis Biotherapeutics from $34.00 to $38.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Finally, Needham & Company LLC increased their price target on Arcutis Biotherapeutics from $36.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.12.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for dermatologic conditions. The company’s portfolio is centered on therapies designed to address inflammatory skin diseases, with an emphasis on nonsteroidal topical medicines that may help patients manage chronic conditions.

Arcutis’s lead product is ZORYVE (roflumilast), a topical phosphodiesterase-4 inhibitor. ZORYVE has received U.S. Food and Drug Administration approvals for multiple dermatological uses, including plaque psoriasis, seborrheic dermatitis and atopic dermatitis, in different cream and foam formulations.